Author, year, country | Last search date | Disease | Countries of included RCTsb | Intervention | Comparison | No. of studies in MA | No. of patients in MA | Eradication rates by ITT | Eradication rates odds ratio (95 % CI) by ITT | Quality assessmenta |
---|---|---|---|---|---|---|---|---|---|---|
Gisbert and Calvet 2012 Spain [48] | December 2011 | HP infection PUD/NUD/others | Germany, UK, Japan, Italy, Japan, Korea (2) | Concomitant therapy: metronidazole + standard triple therapy | Standard triple therapy | 7 | 984 | 90 % vs. 78 % | 2.36 (1.67–3.34) | 0 |
Note: Standard triple therapy: (PPI(ome/rabe/lanso) + amoxicillin + clarithromycin) | ||||||||||
Lv et al. 2015 China [49] | April 2014 | HP infection; PUD/NUD/others; naïve to treatment or had previous treatment | China (4), Taiwan (3), Korea, Turkey | Quadruple regimens containing both amoxicillin and tetracycline | Other quadruple regimens where amoxicillin and tetracycline were not contained together | 9 | 1453 | 78.1 % vs. 80.5 % | 0.90 (0.46–1.78) | + |
US, Italy, Turkey, Taiwan, China | Triple therapy containing both amoxicillin and tetracycline | Other regimens where amoxicillin and tetracycline were not contained together | 5 | 840 | 68.8 % vs. 66.7 % | 1.21 (0.64–2.28) | ||||
Nishizawa et al. 2014 Japan [54] | July 2014 | HP infection | Japan (5), Korea | Rebamipide containing regimen: rebamipide+ | Rebamipide NOT-containing regimen: none or mucosal protective agents other than rebamipide (teprenone/plaunotol)+ | 6 | 611 | 63.5 % vs. 52.7 % | 1.59 (1.14–2.22) | + |
+PPI(lanso/ome) + antibiotics (amoxicillin/metronidazole) |